BNP Paribas Financial Markets
IMRX icon

BNP Paribas Financial Markets’s Immuneering IMRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Buy
2,276
+36
+2% +$185 ﹤0.01% 5185
2025
Q4 		$14.7K Buy
2,240
+1,978
+755% +$12.7K ﹤0.01% 5085
2025
Q3 		$1.83K Sell
262
-25
-9% -$130 ﹤0.01% 5178
2025
Q2 		$967 Hold
287
– – ﹤0.01% 5149
2025
Q1 		$436 Sell
287
-62
-18% -$113 ﹤0.01% 5151
2024
Q4 		$768 Buy
+349
New +$724 ﹤0.01% 5115

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Financial Markets's IMRX Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Immuneering (IMRX) stake by 1.6% in Q1 2026, buying an estimated $185 and bringing the position to 2,276 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #5185.

BNP Paribas Financial Markets first reported a position in IMRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $14.7K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • BNP Paribas Financial Markets held 2,276 shares of Immuneering worth $12K as of Q1 2026.
  • BNP Paribas Financial Markets bought 36 Immuneering shares in Q1 2026, an estimated $185.
  • Immuneering made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5185 holding.
  • BNP Paribas Financial Markets first reported a position in Immuneering in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Immuneering position peaked at $14.7K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.